{"entity":{"id":"smoldering-myeloma","kind":"term","name":"Smouldering myeloma / MGUS","aka":["MGUS","monoclonal gammopathy","monoclonal gammopathy of undetermined significance","smouldering","smouldering myeloma","smoldering myeloma","smoldering","plasma cell dyscrasia","mgus-smouldering","Mayo 20/2/20","20/2/20 criteria","IMWG 2/20/20 risk score","evolving M-protein","high-risk smouldering myeloma"],"tldr":"Early plasma-cell conditions with no organ damage; most never progress, but high-risk smouldering disease is now sometimes treated.","summary":"MGUS progresses at ~1% per year; smouldering myeloma at ~10% per year for five years, higher with the 20/2/20 criteria (M-protein >2 g/dL, >20% plasma cells, free light chain ratio >20). Lenalidomide (E3A06) and daratumumab (AQUILA, 2024: progression HR 0.49) delay progression in high-risk smouldering disease; whether to treat remains debated. iStopMM (Iceland) is screening a whole population.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Monoclonal_gammopathy_of_undetermined_significance","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Monoclonal_gammopathy_of_undetermined_significance"}],"tags":[],"related":["dysplasia","active-surveillance","tumour-markers"],"cancers":["multiple-myeloma"],"sections":["early-detection"],"technologies":[],"targets":[],"drugs":["lenalidomide","daratumumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Clinical"},"route":"/terms/smoldering-myeloma/","neighbours":{"term":[{"id":"active-surveillance-term","kind":"term","name":"Active surveillance and observation","route":"/terms/active-surveillance-term/"},{"id":"dysplasia","kind":"term","name":"Dysplasia (pre-cancerous change)","route":"/terms/dysplasia/"},{"id":"m-protein-free-light-chains","kind":"term","name":"M-protein, immunofixation and serum free light chains","route":"/terms/m-protein-free-light-chains/"},{"id":"tumour-markers","kind":"term","name":"Tumour markers (CEA, LDH, chromogranin, thyroglobulin)","route":"/terms/tumour-markers/"}],"technology":[{"id":"active-surveillance","kind":"technology","name":"Active surveillance","route":"/technologies/active-surveillance/"}],"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"smouldering-myeloma","kind":"cancer","name":"Smouldering multiple myeloma","route":"/cancers/smouldering-myeloma/"}],"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"drug":[{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"}],"trial":[{"id":"istopmm","kind":"trial","name":"iStopMM","route":"/trials/istopmm/"}]}}